Copenhagen-based Ventriject, a MedTech startup specializing in technology for accurately measuring cardiorespiratory fitness (CRF), has secured €1.7 million in a funding round following its expansion into multiple European markets.
Led mainly by existing investors, this round builds on previous funding in 2021 and 2024. Participants include the Export and Investment Fund of Denmark (EIFO), TechStation | HardTech Innovation Hub, Investo Capital, and private investor Carsten Stendevad, a former CEO of a major Danish pension fund.
CEO Mikkel Kristiansen expressed to EU-Startups: “We are proud of the ongoing trust from our existing and new investors. There’s been significant interest in our company over the past year from customers, partners, and investors. Our product fits well with the current focus on preventative health and living healthier and longer lives.
“We see this in our European markets and are also noticing interest from the American market. The upcoming period is exciting for us, and this capital will support our ongoing journey.”
VentriJect, a spinout from Aalborg University in Denmark, was founded in 2018 and had a commercial-ready product by 2021. Its technology has medical and fitness applications, facilitating its rapid EU expansion since its first major funding in 2021.
Their flagship device, the Seisomofit, is a CE-marked medical device utilizing seismocardiography to measure chest wall movements from heart vibrations.
With the Seismofit system, a person’s cardiorespiratory fitness (VO2 max) can be estimated in under 3 minutes without exercise. The VentriJect app delivers this measurement using their algorithm.
Anders Throup-Jensen from EIFO commented, “We are pleased to have invested in VentriJect’s latest round. As investors since 2021, we believe in VentriJect’s future as a market leader in VO2 Max measurements. The team’s market expansion ability has been impressive, and I anticipate working together as we grow our EU and US sales.”
CEO Kristiansen notes VentriJect benefits from a broader boom in the Nordic startup scene, with interest growing in healthtech. He mentions a €48 million investment by Novo Holdings and EIFO into the HealthCap IX fund focused on Nordic HealthTech as an example of VC investment recognizing the region’s medical technology opportunities.
The startup reports having customers in several European markets and has signed distributors in Denmark, the Netherlands, Sweden, Switzerland, and the UK.
They are negotiating with European healthcare providers and exploring US market entry, accessing over 55,000 health clubs and the largest global healthcare market.